Treatment Guidelines for the Initiation Administration and ...
Canberra Hospital and Health ServicesClinical Procedure Treatment for the Initiation, Administration and Monitoring of People on Olanzapine Long-Acting Injection (LAI)Contents TOC \h \z \t "Heading 1,1,Heading 2,2" Contents PAGEREF _Toc494184400 \h 1Purpose PAGEREF _Toc494184401 \h 2Scope PAGEREF _Toc494184402 \h 2Section 1 – Olanzapine PAGEREF _Toc494184403 \h 2Section 2 – Liaison Considerations Prior to Commencing Olanzapine LAI PAGEREF _Toc494184404 \h 2Section 3 – Starting Dose of Olanzapine LAI PAGEREF _Toc494184405 \h 3Section 4 - Reconstitution PAGEREF _Toc494184406 \h 4Section 5 - Administration PAGEREF _Toc494184407 \h 4Section 6 – Adverse Effects PAGEREF _Toc494184408 \h 4Section 7 – Observation and Monitoring PAGEREF _Toc494184409 \h 5Related Policies, Procedures, Guidelines and Legislation PAGEREF _Toc494184410 \h 6Search Terms PAGEREF _Toc494184411 \h 6Attachments PAGEREF _Toc494184412 \h 6Attachment A - Clinical Decision Making Process for use of Olanzapine LAI PAGEREF _Toc494184413 \h 7PurposeThe purpose of this Procedure is to provide a framework for Mental Health, Justice Health & Alcohol and Drug Services (MHJHADS) to provide safe and effective treatment in the prescription, administration and monitoring of Olanzapine LAI. Back to Table of ContentsScopeThis Procedure pertains to all MHJHADS clinical staff involved in the initiation, maintenance and monitoring of people accessing MHJHADS services on Olanzapine LAI. Back to Table of ContentsSection 1 – Olanzapine Olanzapine pamoate (Zyprexa Relprevv):Long-acting injectable form of Olanzapine given every 2 or 4 weeks.Indicated for maintenance treatment of Schizophrenia.Is different to Olanzapine IM (Zyprexa IM), which is a short acting intramuscular injection used for acute agitation and arousal.Olanzapine LAI is suitable for people who:Are non-adherent to oral medication or who cannot guarantee adherence; Have responded well to and tolerated oral Olanzapine; Are able to agree to a 2 hour supervision/monitoring period (see Observation and Monitoring); Are being followed up by a clinic that can accommodate a 2 hour observation period; and Where there is a reasonable expectation that the use of Olanzapine LAI will provide significant benefit to that individual.Back to Table of ContentsSection 2 – Liaison Considerations Prior to Commencing Olanzapine LAIThe practical feasibility and governance of Olanzapine LAI use will be negotiated with the appropriate Community Mental Health Service, at an early stage in the decision making process. See Attachment A. Clinical Decision Making Process for use of Olanzapine LAI.NOTE: When it is planned to start Olanzapine LAI, an email confirming capacity to manage the observation period at BHRC (or Woden) must be sent to the Chief Psychiatrist before the LAI is initiated. Before starting a person on Olanzapine LAI ensure that:The person has had a trial of oral Olanzapine. (This will rule out hypersensitivity and confirm efficacy).Safety precautions and need for the 2 hour observation period after each injection are discussed with the person.The person has agreed to the observation period as an inpatient and outpatient.The person will be able to receive Olanzapine LAI at their follow-up with clinic/Doctor.It would be expected that benefits and side effects would be explained to the person by the Doctor. Where there is an identified carer/nominated person the information would also be conveyed and the support of the carer/nominated person would be acknowledged in the treating plan. Back to Table of Contents Section 3 – Starting Dose of Olanzapine LAIThe person must be trialled on oral Olanzapine prior to starting treatment with the long-acting injection (LAI).Establish an effective and tolerable oral dose.Supplementation with oral Olanzapine is not required at the start of treatment.Initiate Olanzapine LAI at a dose recommended in the table belowTotal oral olanzapine DoseRecommended starting dose of olanzapine pamoateMaintenance dose after 2 months of olanzapine pamoate treatment10mg/day210mg/2 weeks or405mg/4 weeks150mg/2 weeks or 300mg/4 weeks15mg/day300mg/2 weeks210mg/2 weeks or405mg/4 weeks20mg/day300mg/2 weeks300mg/2 weeksDoses greater than 405mg/4 weeks or 300mg/2 weeks have not been studied in clinical trials.Back to Table of ContentsSection 4 - ReconstitutionUse only the supplied diluent to reconstitute powder.Each vial strength requires a different amount of diluent to be added, but the result is always a solution with an Olanzapine concentration 150mg/mL.DoseZyprexa Relprevv Vial StrengthVolume of Diluent to add150mg210mg1.3ml210mg210mg1.3ml300mg300mg1.8ml405mg405mg2.3mlBack to Table of ContentsSection 5 - AdministrationOlanzapine LAI is for deep gluteal intramuscular use.DO NOT administer into the deltoid muscle. DO NOT administer intravenously or subcutaneously.Back to Table of ContentsSection 6 – Adverse EffectsPotential inadvertent intravascular injection events have occurred with Olanzapine LAI, leading to symptoms of overdose (referred to as Post-Injection Syndrome).All other adverse effects occurred at a similar incidence as oral Olanzapine.Post-Injection Syndrome (PIS)Appears to occur due to intravascular administration of a portion of the dose.Symptoms are consistent with Olanzapine overdose – sedation, dizziness, confusion, slurred speech, altered gait, weakness or unconsciousness.Most reports were classified as mild, however rarely it can result in coma.PIS has occurred in 0.07% of injections, can occur in a person more than once and with any injection.Approximately 80% of events occur within 1 hour of injection; one case was reported to have occurred more than 3 hours after injectionPrecautions to take:Prior to administering the injection observe and note if the person is alert and orientated. Aspirate the syringe prior to injection – if blood is visible discard syringe and inject in different site.Back to Table of ContentsSection 7 – Observation and MonitoringAll people on Olanzapine LAI must be observed for 2 hours post injection, with 30 mins observation and transported home. The observation period is coordinated through the Team Manager of Brian Hennessey Rehabilitation Centre (BHRC). A discussion MUST occur prior to administration to arrange logistics. A community option for observation can be arranged subject to operational capacity, and the commitment from the clinical manager to be with the person throughout the observational period to ensure policy compliance.Managing 2 hour observation period: The person MUST be observed for 2 HOURS after each injection.Observation to be conducted by appropriately trained staff.Actively monitor person for alertness every 30 minutes to confirm the person is alert, oriented and signs and symptoms of overdose are absent.In the wards, the person is to remain on ward and is NOT to be given leave or ground access during this 2 hour period.In community mental health clinics, the person is to remain in the clinic during this 2 hour period. Ideally transport should be arranged for the person’s return home but accompaniment by a health professional is no longer required after 2 hour period of observation. If an overdose is suspected, close medical supervision and monitoring is recommended until symptoms have resolved.For the remainder of the day the person must be vigilant for symptoms of PIS, be able to obtain medical assistance and cannot drive a car or operate machinery.Should the person leave the clinic prior to the end of the monitoring period or refuse to return to the clinic after leaving, an assessment must be made by the treating Consultant Psychiatrist (or if not available, another Consultant Psychiatrist/Psychiatry Registrar) regarding the follow-up plan required. This includes but is not limited to phone contact with the person or home visiting the person after administration. Review of the person’s suitability for Olanzapine LAI must occur where a person repeatedly leaves the clinic prior to the conclusion of the 2 hour observation period.Back to Table of ContentsRelated Policies, Procedures, Guidelines and LegislationLegislationHealth Practitioner Regulation National Law (ACT) 2009Health Records (Privacy and Access) Act 1997Human Rights Act (2004)Medicines, Poisons and Therapeutic Goods Act (ACT) 2008Mental Health Act 2015PoliciesMedication Handling PolicyStandards National Mental Health Standards 2010ACHS EQuIP 5. Clinical 1.5.1 & Corporate 3.1.1Back to Table of ContentsSearch Terms Olanzapine, Long Acting Injection, LAI, MHJHADS, Chief PsychiatristBack to Table of ContentsAttachmentsAttachment A - Clinical Decision Making Process for use of Olanzapine LAIDisclaimer: This document has been developed by ACT Health, Canberra Hospital and Health Service specifically for its own use. Use of this document and any reliance on the information contained therein by any third party is at his or her own risk and Health Directorate assumes no responsibility whatsoever.Date AmendedSection AmendedApproved ByEg: 17 August 2014Section 1ED/CHHSPC ChairAttachment A - Clinical Decision Making Process for use of Olanzapine LAINOTE: As of March 2013 the observation period has been reduced to 2 hours (from 3) and there is no longer a requirement to be transported home by a health professional after 2 hour observation period. ................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- basketball in season training plan day 1
- summer basketball workout
- treatment guidelines for the initiation administration and
- example data and safety monitoring plan dsmp independent
- patient and intervention characteristics
- football in season training plan day 1
- foundations of personal fitness skyline garcia s mind
- training plan
Related searches
- stemi treatment guidelines 2018
- chf treatment guidelines 2019
- hypertension treatment guidelines 2019 pdf
- treatment guidelines for cough
- cdc influenza treatment guidelines 2019
- conjunctivitis treatment guidelines 2019
- wcb medical treatment guidelines reference
- nys medical treatment guidelines 2018
- cad treatment guidelines aha
- hypertension treatment guidelines 2019
- osteopenia treatment guidelines 2019 pdf
- benefit administration for the self employed